News & Events

Women�??s sexual health company, TivaMed, today announced it has changed its name to Viveve as it prepares for a 2010 launch of its Viveve system to OB/GYNs in select U.S. markets.

> Read More

Sunshine Heart, Inc (ASX: SHC), a global medical device company focused on innovative heart assist technologies, announces the retirement of Mr Don Rohrbaugh as a director of the Company effective 31 October 2009. The company further announces the appointment of Mr David Rosa as a director of the Company effective 1 November 2009.

> Read More

ChemGenex Pharmaceuticals Limited (ASX:CXS) is pleased to announce Chief Executive Officer and Managing Director Greg Collier, PhD. was recognized this morning for his outstanding contribution to the advancement of biotechnology in Australia.

> Read More

Phase 1/2 clinical trial results with KB001, a Humaneered�?�, high-affinity antibody fragment under development by KaloBios Pharmaceuticals, Inc. in cystic fibrosis patients showed an acceptable safety profile as well as trends toward reducing tissue inflammation and clearance of the bacterium. Results of the multi-center, randomized, double-blind, single-dose, placebo-controlled study are being presented ...

> Read More

NEWARK, CALIF., October 13, 2009 �?? Novasys Medical, Inc., a developer of innovative therapies in women�??s health, announced today that its Renessa® non-surgical treatment for female stress urinary incontinence (SUI) was inducted into the Phoenix Hall of Fame as the 2009 Most Promising New Product at the Phoenix Medical Device and Diagnostic Conference for Chief Executive Officers.

> Read More

> Read More

Sunshine Heart (ASX: SHC), a global medical device company focused on innovative heart assist technologies, announced today an update on the first four patients implanted with the C-Pulse device at The Ohio State University Medical Center in Columbus, Ohio and Jewish Hospital in Louisville, Kentucky.

> Read More

ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO�?� (omacetaxine mepesuccinate). OMAPRO�?� is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.

> Read More

ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that Greg Collier, PhD, Chief Executive Officer and Managing Director will present a company update

> Read More

Peplin, Inc. (ASX:PLI) today announced a definitive merger agreement whereby LEO Pharma A/S (LEO), a privately-held, leading global pharmaceutical company within Dermatology and Critical Care, will acquire all outstanding securities of Peplin for approximately US$287.5 million (currently A$348.4 million) in cash. This represents a purchase price of US$16.99 per common share of Peplin stock or A$1.03 per Peplin CHESS Depositary Interest (CDI).1

> Read More

Peplin Inc (ASX:PLI), a clinical stage dermatology company, today announced a definitive agreement whereby Leo Pharma A/S (Leo), a privately-held, leading global pharmaceutical company within Dermatology and Critical Care, will, subject to shareholder approval and other closing conditions, acquire all outstanding securities of Peplin.

> Read More

Novasys Medical, Inc., a developer of innovative therapies in women�??s health, announced today that Palmetto GBA and TrailBlazer Health Enterprises, LLC---- two large regional Medicare carriers serving over 10.2 million beneficiaries in California, Nevada, Hawaii, Texas, Oklahoma, Colorado, New Mexico and Virginia-----have agreed to cover the Renessa® treatment for female SUI (stress urinary incontinence) in appropriately selected patients with documented medical necessity.

> Read More

Verva Pharmaceuticals Ltd. and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) today announced the completion of an agreement providing Isis an exclusive license to Verva's intellectual property rights targeting the Fibroblast Growth Factor Receptor (FGFR) with antisense technology for the treatment of diseases, including obesity and other metabolic disorders. Isis also obtains a right of first refusal to license Verva's intellectual property rights targeting FGFR with mechanisms other than antisense, such as small molecule and antibody technologies. Verva received an undisclosed upfront payment and is eligible for future milestone payments and royalties.....

> Read More

Xenome Limited (�??Xenome�?�) today announced that Dr Julie Cherrington has joined the Xenome Board as an independent, Non-Executive Director....

> Read More

Sunshine Heart, Inc. (ASX: SHC), a global medical device company focused on innovative technologies for advanced heart failure, announced today that Jewish Hospital in Louisville, Kentucky has completed implants of the Company�??s C- PulseTM heart assist system in two female patients, ages fifty-eight and fifty-five, respectively, under a clinical trial approved by the US Food and Drug Administration (FDA). These procedures mark the first US female patients and the third and fourth patients treated with the C-Pulse heart assist system...

> Read More

Sunshine Heart, Inc. (ASX: SHC) is pleased to announce the successful completion of a private placement to sophisticated and institutional investors in Australia to raise $1.75 million, being 15% of issued capital and the maximum amount which could be raised by the company through the placement without shareholder approval...

> Read More

Xenome Limited (�??Xenome�?�) today announced it has executed a research collaboration agreement with Axxam SpA (�??Axxam�?�), a leading biotechnology research organization offering early-stage discovery research services for the life science industry....

> Read More

Sunshine Heart (ASX: SHC), a global medical device company focused on innovative heart assist technologies, announced today that the first two patients implanted with the C-Pulse device in April 2009 at The Ohio State University Medical Center in Columbus, Ohio have successfully completed their 3 month follow-up evaluation....

> Read More

Peplin, Inc. (ASX:PLI) today announced the initiation of its second non-head Phase 3 clinical trial to confirm the efficacy and safety of PEP005 (ingenol mebutate) gel for the treatment of actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, when applied to non-head locations, which include the trunk and extremities...

> Read More

Novasys Medical, Inc., developer of the Renessa® treatment for female stress urinary incontinence, announced today that it has received $18.95 million in the second tranche of its previously announced Series D preferred stock financing. The Company received the first tranche of the Series D round in May 2008, with lead investor Versant Ventures and new investors ThreeArch Partners and Skyline Ventures. All three participated in the second tranche, with existing investors Alloy Ventures, Delphi Ventures, GBS Venture Partners and Hercules Technology Growth Capital.

> Read More

ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that it has appointed Mr. Thomas DeZao to the position of Senior Vice President and Chief Commercial Officer. Mr. DeZao will commence his position immediately and will lead the company�??s commercial efforts including sales, marketing and the coordination of manufacturing activities for the launch of omacetaxine in the USA...

> Read More

Nuon Therapeutics, Inc., a clinical stage, privately-held biopharmaceutical company focused on novel therapies for autoimmune and inflammatory diseases, today announced the appointments of Paulette Dillon to the position of chief business officer and Tito Serafini, Ph.D., to the position of chief scientific officer, both reporting to president and CEO Rodney Pearlman, Ph.D...

> Read More

Nuon Therapeutics, Inc., a clinical stage, privately-held biopharmaceutical company focused on novel therapies for autoimmune and inflammatory diseases, announced today that Arlene Morris, president and CEO of Affymax, Inc. (Nasdaq: AFFY), has been elected chairperson of the company�??s Board of Directors. A proven commercial leader in the biotechnology and pharmaceutical industry with more than 25 years of experience, Ms. Morris is well suited to work with the management team at Nuon Therapeutics....

> Read More

ChemGenex Pharmaceuticals Limited (ASX:CXS) advises that a decision has been taken by the Board to seek a voluntary de-listing from the NASDAQ Capital Market (�??NASDAQ�?�) and to fully deregister from the U.S. Securities and Exchange Commission�??s (�??SEC�?�) ongoing reporting obligations....

> Read More

ChemGenex Pharmaceuticals Limited (ASX:CXS), announced today that the results of pre-clinical research which demonstrated that omacetaxine kills model human leukemic stem cells were presented as the14th Congress of the European Hematology Association (EHA) in Berlin, Germany on Sunday. Human leukemic stem cells are known to be insensitive to tyrosine kinase inhibitors (TKIs), the drug family currently approved to treat Chronic Myeloid Leukemia (CML). The work was carried out in collaboration with Professor Tessa Holyoake at the University of Glasgow, Scotland, UK....

> Read More